These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 2370248)

  • 21. Synthesis and antitumor activity of [1,2-bis(4-fluorophenyl)ethylenediamine][dicarboxylato]platinum(II) complexes.
    Gust R; Krauser R; Schmid B; Schönenberger H
    Arch Pharm (Weinheim); 1998 Jan; 331(1):27-35. PubMed ID: 9507699
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and in vitro and in vivo antitumor activity of a series of trans platinum antitumor complexes.
    Kelland LR; Barnard CF; Evans IG; Murrer BA; Theobald BR; Wyer SB; Goddard PM; Jones M; Valenti M; Bryant A
    J Med Chem; 1995 Aug; 38(16):3016-24. PubMed ID: 7636864
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of a parenterally administrable hydrosol preparation of the "third generation platinum complex" [(+/-)-1,2-bis(4-fluorophenyl)ethylenediamine]dichloroplatinum(II). Part 1. Preparation and studies on the stability and antitumor activity.
    Gust R; Bernhardt G; Spruss T; Krauser R; Koch M; Schönenberger H; Bauer KH; Schertl S; Lu Z
    Arch Pharm (Weinheim); 1995 Sep; 328(9):645-53. PubMed ID: 7487421
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Investigation of the conformational influences on the estrogenic activity of 1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamines and of their platinum(II) complexes, II: Synthesis and studies on the estrogenic activity of cis- and trans[bis(2,6-dichloro-4-hydroxybenzylamine)]dihaloplatinum(II)-c omplexes.
    Gust R; Schönenberger H
    Arch Pharm (Weinheim); 1994 Dec; 327(12):763-9. PubMed ID: 7872853
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preclinical activity of a new platinum analogue, lobaplatin, in cisplatin-sensitive and -resistant human testicular, ovarian, and gastric carcinoma cell lines.
    Harstrick A; Bokemeyer C; Scharnofkse M; Hapke G; Reile D; Schmoll HJ
    Cancer Chemother Pharmacol; 1993; 33(1):43-7. PubMed ID: 8269588
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]- dichloroplatinum(II), a new drug not only parenterally but also orally active in the therapy of breast and prostate cancer.
    Spruss T; Schertl S; Schneider MR; Gust R; Bauer K; Schönenberger H
    J Cancer Res Clin Oncol; 1993; 119(12):707-16. PubMed ID: 8408183
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selective potentiation of platinum drug cytotoxicity in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines by amphotericin B.
    Sharp SY; Mistry P; Valenti MR; Bryant AP; Kelland LR
    Cancer Chemother Pharmacol; 1994; 35(2):137-43. PubMed ID: 7987990
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor-inhibiting [1,2-bis(fluorophenyl)ethylenediamine]platinum(II) complexes. V. Synthesis and evaluation of enantiomeric [1,2-bis-(4-fluorophenyl)ethylenediamine]dichloroplatinum(II) complexes.
    vom Orde HD; Reile H; Müller R; Gust R; Bernhardt G; Spruss T; Schönenberger H; Burgemeister T; Mannschreck A
    J Cancer Res Clin Oncol; 1990; 116(5):434-8. PubMed ID: 2229132
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Does [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]- dichloroplatinum(II) act on the hormone-sensitive, murine breast cancer as a biological response modifier? Part 1: The MXT-M-3.2 breast cancer stimulates the growth of an identical second graft; [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]dichloroplat inum (II) inhibits this process.
    Schlemmer R; Spruss T; Bernhardt G; Schönenberger H
    Arch Pharm (Weinheim); 2000 Mar; 333(2-3):69-71. PubMed ID: 10783521
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.
    Kelland LR; Abel G; McKeage MJ; Jones M; Goddard PM; Valenti M; Murrer BA; Harrap KR
    Cancer Res; 1993 Jun; 53(11):2581-6. PubMed ID: 8388318
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cellular pharmacology of cis and trans pairs of platinum complexes in cisplatin-sensitive and -resistant human ovarian carcinoma cells.
    O'Neill CF; Hunakova L; Kelland LR
    Chem Biol Interact; 1999 Nov; 123(1):11-29. PubMed ID: 10597899
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel trans-platinum coordination complex possessing in vitro and in vivo antitumor activity.
    Kelland LR; Barnard CF; Mellish KJ; Jones M; Goddard PM; Valenti M; Bryant A; Murrer BA; Harrap KR
    Cancer Res; 1994 Nov; 54(21):5618-22. PubMed ID: 7923207
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reversible and irreversible interactions of a cisplatin analog bearing a 1,2-diphenylethylenediamine ligand with plasma and plasma proteins in vitro.
    Bednarski PJ; Kratochwil NA; Otto AM
    Drug Metab Dispos; 1994; 22(3):419-27. PubMed ID: 7520852
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of glutathione (GSH) in determining sensitivity to platinum drugs in vivo in platinum-sensitive and -resistant murine leukaemia and plasmacytoma and human ovarian carcinoma xenografts.
    Goddard P; Valenti M; Kelland LR
    Anticancer Res; 1994; 14(3A):1065-70. PubMed ID: 8074451
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Aqua-1-(2,6-dichloro-4-hydroxyphenyl)-2-phenylethylenediamine] sulfatoplatinum(II) complexes with variable substituents in the 2-phenyl ring. 3. Investigation of breast cancer inhibiting properties.
    Gust R; Faderl M; Schönenberger H
    J Cancer Res Clin Oncol; 2000 Nov; 126(11):647-54. PubMed ID: 11079729
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biochemical pharmacology of homologous alicyclic mixed amine platinum(II) complexes in sensitive and resistant tumor cell lines.
    Yoshida M; Khokhar AR; Siddik ZH
    Cancer Res; 1994 Jul; 54(13):3468-73. PubMed ID: 8012968
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of novel ammine/amine platinum (IV) dicarboxylates in L1210 murine leukaemia cells sensitive and resistant to cisplatin, tetraplatin or carboplatin.
    Orr RM; O'Neill CF; Nicolson MC; Barnard CF; Murrer BA; Giandomenico CM; Vollano JF; Harrap KR
    Br J Cancer; 1994 Sep; 70(3):415-20. PubMed ID: 8080724
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cationic nonsymmetric transplatinum complexes with piperidinopiperidine ligands. Preparation, characterization, in vitro cytotoxicity, in vivo toxicity, and anticancer efficacy studies.
    Najajreh Y; Khazanov E; Jawbry S; Ardeli-Tzaraf Y; Perez JM; Kasparkova J; Brabec V; Barenholz Y; Gibson D
    J Med Chem; 2006 Jul; 49(15):4665-73. PubMed ID: 16854072
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Asymmetrically substituted ethylenediamine platinum(II) complexes as antitumor agents: synthesis and structure-activity relationships.
    Mailliet P; Segal-Bendirdjian E; Kozelka J; Barreau M; Baudoin B; Bissery MC; Gontier S; Laoui A; Lavelle F; Le Pecq JB
    Anticancer Drug Des; 1995 Jan; 10(1):51-73. PubMed ID: 7695813
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative cytotoxicity of CI-973, cisplatin, carboplatin and tetraplatin in human ovarian carcinoma cell lines.
    Perez RP; O'Dwyer PJ; Handel LM; Ozols RF; Hamilton TC
    Int J Cancer; 1991 May; 48(2):265-9. PubMed ID: 2019469
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.